TPIDB > Principal Investigator
Principal Investigator
Linkou Chang Gung Medical Foundation
(在職)
Division of Dermatology
Division of Others-Immunodermatology, Adverse drug reactions, Drug hypersensitivity, Pharmacogenomics
Division of General Internal Medicine
Taipei Chang Gung Medical Foundation
(在職)
Division of Dermatology
Division of Others-Immunodermatology, Adverse drug reactions, Drug hypersensitivity, Pharmacogenomicspsoriasis,
Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung
Division of Dermatology
更新時間：2023-10-24
鐘文宏Chung, Wen-Hung
- Principal Investigator
- Clinical Trial Experience (year) 17 years 9 個月
-
chung1@cgmh.org.tw
Publication
82Publications
61
22. Wang CW, Dao RL, Chung WH. Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions. Curr Opin Allergy Clin Immunol. 2016 Aug;16(4):339-45. (SCI; IF=4.41; Allergy: 10/25; Immunology: 79/151)
62
21. Su SC, Hsieh MJ, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017 Jan;62(1). (SCI; IF=9.314; Endocrinology & metabolism: 5/133; Neurosciences: 14/256; Physiology: 3/83)
63
20. Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC, Hui RC, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Sun PL, Lee HE, Yang CY, Kao PH, Yang CH, Ho HC, Lin JY, Chang YC, Chen MJ, Lu CW, Ng CY, Kuo KL, Lin CY, Yang CS, Chen DP, Chang PY, Wu TL, Lin YJ, Weng YC, Kuo TT, Hung SI, Chung WH*; Taiwan Severe Cutaneous Adverse Reaction Consortium. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017 Jan 3;88(1):78-86. (SCI; IF=8.166; Clinical Neurology: 8/193)
64
19. Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH*. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol. 2017 May;137(5):1065-1073. (SCI; IF=6.915; Dermatology: 1/61)
65
18. Pan RY, Dao RL, Hung SI, Chung WH*. Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. Clin Pharmacol Ther. 2017 Mar 15. doi: 10.1002/cpt.683. [Epub ahead of print] (SCI; IF=7.268; Pharmacology & pharmacy: 10/255)
66
17. Chen TJ, Chung WH, Chen CB, Hui RC, Huang YH, Lu YT, Wang CW, Wang KH, Yang LC, Hung SI. Methotrexate-induced epidermal necrosis: A case series of 24 patients. J Am Acad Dermatol. 2017 Aug;77(2):247-255.(co-first author) (SCI; IF=7.002; Dermatology: 1/63)
67
16. Lin CY, Wang CW, Hui CR, Chang YC, Yang CH, Cheng CY, Chen WW, Ke WM, Chung WH*. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018 Jan;73(1):221-229. (SCI; IF=7.361; Allergy: 2/23; Immunology: 19/137).
68
15. Fan WL, Shiao MS, Hui RC, Su SC, Wang CW, Chang YC, Chung WH*. HLA Association with Drug-Induced Adverse Reactions. J Immunol Res. 2017;2017:3186328. doi: 10.1155/2017/3186328. Epub 2017 Nov 23. (SCI; IF=3.276; Immunology: 63/151).
69
14. Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH*. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018 Mar 1;128(3):985-996. (SCI; IF=12.784; Medicine, research & experimental: 4/128).
70
13. Chen WT, Wang CW, Lu CW, Chen CB, Lee HE, Hung SI, Choon SE, Yang CH, Liu MT, Chen TJ, Fan WL, Su SC, Lin YY, Chang YC, Chung WH*; Taiwan Severe Cutaneous Adverse Reaction Consortium. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol. 2018 Jul; 138(7):1546-1554. (SCI; IF=6.287; Dermatology: 2/63)
